MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism
ConclusionsThis study sheds light on miRNA-3662 inhibits PDAC cell chemoresistance and aerobic glycolysis through a negative feedback loop with HIF-1 ɑ. Therefore, the co-delivery of miR-3662 and Gem could be served as a promising therapeutic regimen for PDAC patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Fish | Genetics | Pancreas | Pancreatic Cancer | Study